For Incubators & Accelerators
A Vantage Incubator Report gives one company the eight-domain, cited read an investor would run, plus where it sits against the rest of your cohort, reviewed by a physician and a biomedical engineer. Programs that want every company read can run it as an annual cohort license.
The Challenge
Few programs have in-house clinical, regulatory and engineering reviewers to read each company the way an investor’s diligence will.
Vantage reads the public record and the materials a company provides across regulatory, clinical, IP, reimbursement, commercial, team, financial and competitive position, with sources. Program staff and founders see the questions an investor will raise before demo day, and decide for themselves what to do about them.
Assessment Scope
Eight domains, each tied to its sources. See the methodology →
510(k), De Novo or PMA routing, predicate availability, and what comparable products went through.
CPT/HCPCS codes, coverage policies and coding gaps on record.
Registered and published studies, the evidence comparable products brought to market, and fit with clinical workflow.
Patent landscape, claim coverage and freedom-to-operate questions from USPTO records.
Design-for-manufacturability, supplier concentration and quality-system questions for the engineering review.
Domain experience on record, gaps in regulatory and clinical leadership, and the assumptions in the commercial plan.
What a report helps answer
Each report sets out what the record shows across eight domains, with sources, and where the company sits against the rest of your cohort. It is a read, not a verdict: program staff and founders decide what to do with it.
The same domains an investor’s diligence examines — regulatory path, evidence, IP, reimbursement and the rest — with the record behind each question, before the pitch rather than during it.
Each Incubator Report is reviewed by Arvind Ravinutala, MD, for the clinical and regulatory picture and by Aswini Ravinutala, BME, for the technology, design and manufacturing questions, with a 30-minute debrief.
Every company in a cohort license is read against the same eight domains and the same public sources, so the reports can be compared side by side.
Use Cases
Cohort-wide reads at intake, mid-program or before demo day, so founders see the questions investors will raise while there is still time to address them.
A shared, cited picture of each company’s open questions for staff and mentors to work from.
A consistent read on each venture a studio is building, with sources, before capital and attention are committed.
Pricing for Incubators & Accelerators
Start with a single company. Programs that want every company read can set up an annual cohort license, scoped with you on a call.
Per-company diligence in cohort context: the eight-domain read, plus where the company sits against the rest of your cohort.
Every company in the cohort read on the same consistent basis. The number of companies and the timing are set with you on the call.
Screening at intake? The Quick Screen is $5,000 per company: automated, six independent signals linked to their source records, with no composite score or verdict. The fee credits in full toward a larger engagement. See the Quick Screen →
Deliverables
Every report opens with an executive summary. The sample uses an illustrative company.
See a sample report →Every report is delivered under our standard engagement terms. It is independent diligence on the public record and the materials a company provides — not legal advice, not investment advice and not a prediction of commercial outcomes.
Your Review Team
Arvind Ravinutala, MD, is a practicing physician and chairs a Pharmacy and Therapeutics (P&T) Committee. Aswini Ravinutala, BME, is a biomedical engineer with 10+ years in medical devices and is R&D Manager at Spiro Medical. Meet the team →
The regulatory, clinical and commercial red flags we look for, written by Arvind Ravinutala, MD, and Aswini Ravinutala, BME.
Get the guideBook a free 20-minute call to talk through a company or your whole cohort, and whether single reports or a cohort license fits. No obligation.